IGF-1R targeting in cancer - does sub-cellular localization matter?

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Insulin-like growth factor receptor (IGF-1R) is a key target in cancer therapy.
• Previous IGF-1R-targeted drugs faced challenges with resistance, toxicity, and lack of patient stratification.
• Despite clinical trial failures, there's renewed interest in IGF-1R therapeutics.

Purpose of the Study:

• To review the history of IGF-1R targeted drug development.
• To explore the potential of IGF-1R sub-cellular localization as a predictive biomarker.
• To investigate the correlation between IGF-1R localization and treatment susceptibility.

Main Methods:

• Review of clinical trial data and scientific literature.
• Analysis of resistance and toxicity mechanisms.
• Exploration of biomarker-driven patient stratification.

Main Results:

• Early clinical trials highlighted resistance and toxicity issues with IGF-1R inhibitors.
• Sub-cellular localization of IGF-1R emerged as a potential predictive biomarker.
• Lack of patient stratification limited the success of prior therapeutic strategies.

Conclusions:

• Next-generation IGF-1R therapies require predictive biomarkers for patient selection.
• Sub-cellular localization of IGF-1R shows promise for guiding treatment decisions.
• Combination therapies incorporating IGF-1R inhibitors may benefit from this biomarker approach.